Brown vs white adipocytes: The PPARγ coregulator story  by Koppen, Arjen & Kalkhoven, Eric
FEBS Letters 584 (2010) 3250–3259journal homepage: www.FEBSLetters .orgReview
Brown vs white adipocytes: The PPARc coregulator story
Arjen Koppen a,b, Eric Kalkhoven a,b,c,*
aDepartment of Metabolic and Endocrine Diseases, UMC Utrecht, Lundlaan 6, 3584 EA Utrecht, The Netherlands
bNetherlands Metabolomics Centre, The Netherlands
cDepartment of Paediatric Immunology, UMC Utrecht, Lundlaan 6, 3584 EA Utrecht, The Netherlands
a r t i c l e i n f o a b s t r a c tArticle history:
Received 14 May 2010
Revised 21 June 2010
Accepted 22 June 2010
Available online 30 June 2010
Edited by Wilhelm Just
Keywords:
Adipogenesis
Transcription
Coactivator
Corepressor
White and brown adipose tissue
PPARgamma0014-5793/$36.00  2010 Federation of European Bio
doi:10.1016/j.febslet.2010.06.035
* Corresponding author at: Department of Metab
UMC Utrecht, Lundlaan 6, 3584 EA Utrecht, The Neth
E-mail address: e.kalkhoven@umcutrecht.nl (E. KaThe development of adipose tissue is a process which involves the concerted cooperation of numer-
ous transcription factors together with their coactivators and corepressors. The peroxisome prolif-
erator-activated receptor c (PPARc) is considered to be one of the master regulators of adipocyte
differentiation. The presence of two functionally distinct types of adipose tissue, white and brown
(WAT and BAT), requires an even more complex regulation of adipose tissue development. In this
review we will focus on the role of PPARc coregulators in adipogenesis and especially on the role
of PPARc coregulators in white and brown adipose tissue. Speciﬁcity in coregulator function in
WAT and BAT may form an additional level of regulation of adipose tissue development.
 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. White and brown adipose tissue
White adipose tissue (WAT) has long been recognized as a stor-
age facility for excess energy derived from food intake [1]. Energy
is stored in the form of triglycerides in large lipid droplets in white
adipocytes. In time of caloric need lipases will hydrolyze triglycer-
ides into fatty acids, which in turn can be oxidized in mitochondria
in other tissues to generate energy [2]. More recent developments
in adipose tissue research have shown that WAT is an endocrine
organ, releasing a wide range of adipokines, which for example
regulate immune responses, blood pressure control, angiogenesis,
haemostasis, bone mass and thyroid and reproductive function [3].
Brown adipose tissue (BAT) is specialized for non-shivering
thermogenesis, the process whereby the energy derived from fatty
acid oxidation is used for the generation of heat due to mitochon-
drial uncoupling [4]. In brown adipocytes triglycerides are orga-
nized as multiple small lipid droplets, and there is a high content
of mitochondria [4]. For a long time it was assumed that in humans
BAT was mainly present in infants and relatively scarce in adults
[5]. In contrast, small mammals, even adults, have brown adipose
tissue to defend them against the cold, although the ratio WAT/
BAT varies with genetic background, sex, age, nutritional status
and environmental conditions [6]. Three recent studies, using thechemical Societies. Published by E
olic and Endocrine Diseases,
erlands.
lkhoven).glucose tracer 2-[18F]-ﬂuoro-D-deoxy-D-glucose (FDG) in combina-
tion with computer tomography, showed that also human adults
have distinct BAT deposits [7–9]. In addition, cold induced FDG up-
take, an important characteristic of BAT activity, was fourfold high-
er in lean compared to overweight/obese individuals [8].
White and brown adipocytes both are derived from mesenchy-
mal stem cells (MSC; see Fig. 1a). Precursor cells of WAT reside in
the mural cell compartments of the adipose vasculature and are
positive for PPARc and CD24 expression (reviewed in [10]). Line-
age-tracing experiments in mice have shown that brown adipo-
cytes are derived from Myf5 positive progenitor cells, which also
give rise to myocytes, while white adipocytes are Myf5 negative
[11]. Brown adipocytes have been detected in WAT after chronic
cold exposure or b-adrenergic stimulation [12] and these cells
did not originate from theMyf5 positive progenitor cells [11]. Such
brown adipocytes, which clearly have a distinct developmental ori-
gin from brown adipocytes in BAT, are sometimes referred to as
‘‘brite” or ‘‘beige” adipocytes.
Several cell culture models are used to study adipogenesis. The
most widely used model system for preadipocyte differentiation is
the 3T3-L1 cell line. This cell line, derived from Swiss 3T3 mouse
embryos [13], can be differentiated into mature white adipocytes
upon treatment with an adipogenic cocktail containing insulin,
dexamethasone and IBMX. Knock-down or ectopic overexpression
experiments in 3T3-L1 cells is very often used to study the adipo-
genic potential of proteins, as can also be seen in this review. Other
cell systems used to study adipogenesis include primarylsevier B.V. All rights reserved.
Fig. 1. White and brown adipocyte differentiation and adipogenesis-speciﬁc PPARc coregulators. (a) Schematic representation of the differentiation of mesenchymal stem
cells (MSCs) towards white and brown adipocytes. Cell fate of brown and white adipocytes is determined by their precursors; white adipocytes are derived from Myf5
negative preadipocytes, while brown adipocytes are originated from Myf5 positive precursors, which also can give rise to skeletal muscle cells. PPARc coregulators. White
preadipocytes can be forced to differentiate into brown-like (also referred to as ‘‘brite” or ‘‘beige”) adipocytes, with many of the properties of brown adipocytes, although
these cells have an independent developmental origin. (b) Overview of coactivators (in blue) and corepressors (in red) of PPARc (orange) involved in adipogenesis. The DNA
bindin domain (DBD) and ligand-binding domain (LBD) of PPARc are marked. The presence of one or more NR boxes in coactivators is depicted by LXXLL. When a NR box is
involved in the interaction of PPARcwith the coactivator, the box is green, otherwise the box is red. In case of menin the status of the NR box in the interaction with PPARc is
unclear and therefore contains a brown label. The presence of one or more CoRNR boxes is represented by LXXXIXXXL and the involvement of a box in the interaction with
PPARc is depicted by green (involved) or red (not involved). The arrowheads indicate the domain of PPARc to which the coregulators bind. In the absence of an arrowhead,
there is an interaction, but the PPARc domain involved has not been determined yet. Finally, the brown fat cell icons represent coregulators involved in determining white/
brown adipocyte identity.
A. Koppen, E. Kalkhoven / FEBS Letters 584 (2010) 3250–3259 3251ﬁbroblasts, embryonic stem cells, immortalized ﬁbroblast cell lines
(for example 3T3-NIH), multipotent precursor cells isolated fromadult tissues and other preadipocyte cell lines (including 3T3-
F442A, hMADs and SGBS) [14–16].
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Although white and brown adipocytes follow different routes
from mesenchymal stem cell to adipocyte, they share a similar
transcriptional program. In both cell types PPARc is a key regulator
of differentiation, as has been shown in several genetic knockout
studies [17–19], as well as in numerous cell-based studies (see this
review). PPARc is a member of the peroxisome proliferator-acti-
vated receptor family, of which the ﬁrstly identiﬁed PPARa was
able to respond to various compounds that induce peroxisome pro-
liferation [20]. PPARc was identiﬁed based on homology and on
studies regarding the transcriptional control of the FABP4 gene
[21–23]. Like other members of the PPAR family, PPARc is a ligand
dependent transcription factor which regulates target genes upon
binding to to PPARc Responsive Elements (PPREs) after dimeriza-
tion with RXRs [24,25]. Synthetic PPARc agonists include the thia-
zolidinediones (TZDs), which ameliorate insulin resistance and
lower blood glucose levels in patients with type 2 diabetes [26].
The domain structure of PPARc is that of most nuclear receptors
(NRs). The N-terminus contains a transcriptional activation domain
(AF-1) whose function is ligand-independent. This domain is sub-
ject to various post-translational modiﬁcations (reviewed in
[27]). The C-terminus harbours a ligand dependent transcriptional
activation domain (AF-2), forms the ligand-binding domain (LBD)
and is involved in ligand dependent coregulator interactions
(Fig. 1). Due to alternative promoter usage and alternative splicing
two PPARc isoforms exist: PPARc1 and PPARc2, the latter having a
28 (human) or 30 (mouse) amino acids longer N-terminus [28].
Both isoforms are strongly induced during preadipocyte differenti-
ation [29], but the functional difference still remains elusive.
PPARc directly controls the expression of many genes involved
in they key functions of adipocytes, like lipid transport, lipid
metabolism, insulin signalling and adipokine production [30].
PPARc target genes involved in lipid metabolism regulate pro-
cesses like lipid transport (FABP4) [22], fatty acid uptake (LPL, FATP/
SLC27A1, OLR1) [31–33], recycling of intracellular fatty acids (PEP-
CK/PCK1, GK, AQP7) [34–36] and lipolysis (GPR81) [37]. An impor-
tant mechanism by which PPARc regulates insulin sensitivity is
through the expression of adipokines. For example, adiponectin
expression is increased in adipocytes upon PPARc ligand stimula-
tion, while resistin and TNFa are decreased [38].
The relative new methods of chromatin IP followed by deep
sequencing (ChIP-seq) or microarray analysis (ChIP-chip) have
identiﬁed more than 5000 regions where PPARc can bind in the
genome of differentiated 3T3-L1 cells [39–41]. Amongst these re-
gions a considerable amount of genes was identiﬁed involved in
glucose and lipid metabolic processes and these regions also
showed enhanced RNA polymerase II occupancy and transcription
in adipogenesis [40].3. The role of PPARc coregulators in white and brown
adipogenesis
Since PPARc is important in both WAT and BAT development,
the speciﬁc gene regulatory programs for WAT and BAT may be ex-
plained by tissue-speciﬁc transcription factors than PPARc, or by
differences in activity, usage or expression of certain PPARc coreg-
ulators. In general, NRs activate transcription of target genes in
concert and in association with coregulatory proteins, a class of
proteins that do not bind to DNA themselves. The route from target
gene binding by a NR to gene transcription is a multistep process
which in general involves both recruitment and release of coregu-
lators, chromatin remodelling and activation of the basal transcrip-
tion machinery. Coregulators may effect chromatin remodelling, as
is the case with for instance the p300 and CBP coregulators. Bothproteins contain histone acetyl transferase (HAT) activity and are
able to acetylate nucleosomal histones in target genes, leading to
altered chromatin state an altered accessibility for the polymerase
II transcription machinery [42]. Other coregulators act as a direct
or indirect bridge between NRs and the basal transcription
machinery, hereby enhancing or inhibiting NR-mediated gene
transcription [43,44]. The Mediator complex proteins form a well
described example of such bridging proteins [45]. Interactions be-
tween coregulators and NRs can be regulated by ligands, as exem-
pliﬁed by the ‘‘classical” coactivator SRC-1. Upon ligand
stimulation the NR changes conformation which enables the inter-
action between the LXXLL motif in SRC-1 and the ‘‘charge clamp” in
the LBD of NRs [46,47]. SMRT and NCOR were the ﬁrst corepressors
identiﬁed [48,49], and both contain the CoRNR box motif
(LXXXIXXXL/I) [50] which, similar to the LXXLL motif, forms an
amphipathic helix and binds to the charge clamp of NRs. Upon li-
gand stimulation the afﬁnity for the CoRNR box motif is reduced,
leading to release of the corepressor molecules.
3.1. Steroid Receptor Coactivator (SRC) family of coactivators
The ﬁrst NR coactivator discovered was the Steroid Receptor
Coactivator-1 (SRC-1) [47], originally identiﬁed as a coactivator
for the steroid receptor superfamily. SRC-1 also interacts with
PPARc via LXXLL motifs in a ligand dependent manner [51,52]. Also
for the closely related SRC-2/TIF2 and SRC-3 proteins a direct, li-
gand-dependent, interaction has been shown [53,54], and we have
shown that PPARc can bind SRC-2 and SRC-3 LXXLL motifs in a li-
gand dependent fashion [55]. The metabolic role of SRC family
members emanated from studies with SRC-1 and SRC-2 deﬁcient
mice. SRC-1/ mice are prone to obesity since they display re-
duced energy expenditure, on the other hand SRC-2/ mice show
increased adaptive thermogenesis due to hyperactive BAT, result-
ing in reduced weight gain, improved glucose tolerance and insulin
sensitivity [53]. The effects of SRC-1 and SRC-2 on metabolism are
predominantly mediated by PGC1a (see below). This coregulator,
which controls mitochondrial biogenesis and b-oxidation, is up-
regulated in SRC-2-depleted BAT. In addition, in SRC-2/ mice
the interaction between SRC-1 and PGC1a is facilitated, leading
to an increase in the thermogenic activity of PGC1a [53]. More re-
cently it was shown that also SRC-3 plays in important role in adi-
pogenesis. SRC-3/mice exhibit reduced weight compared to wild
type control mice, and it was suggested that this effect is caused by
a defect in terminal adipocyte differentiation and fat accumulation
in WAT [56]. The SRC-1//SRC-3/ double knockout mice are
lean, resistant to high-fat-diet induced obesity, with no BAT lipid
storage, decreased UCP1 expression and defective adaptive ther-
mogenesis. Despite the higher food intake in these animals, these
animals show increased basal metabolic rates and enhanced phys-
ical activity, resulting in a lean phenotype [57].
In conclusion, these observations suggest that SRC-1 and SRC-2
control the energy balance between WAT and BAT, whereby SRC-1
promotes energy expenditure via fatty acid oxidation in BAT. SRC-2
represses this process by activation of PPARc in WAT, leading to an
increase in triglyceride accumulation inWAT and a decrease in free
fatty acids.
3.2. p300 and CBP
p300 and CREB-binding protein (CBP) are histone acetyl trans-
ferases [58,59] and are well known as NR coactivators. These two
proteins share a high degree of homology, although distinct func-
tions have been described [42]. Both proteins interact with the
LBD of PPARc in a ligand- and LxxLL-dependent fashion, while at
the same time an interaction can be established with the AF-1 do-
main of PPARc [60]. p300 and CBP are capable of enhancing the
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Although studies have shown that both proteins are indispensable
for 3T3-L1 differentiation, the role of p300 and CBP in adipose biol-
ogy has not been ﬁrmly established yet [61]. Furthermore CBP+/
mice display reduced weight of WAT due to reduced triglyceride
accumulation in WAT, but no BAT phenotype. Also these mice
are more insulin sensitive, more glucose tolerant and protected
from high-fat diet induced weight gain [62]. The differential effect
on WAT and BAT development observed in CBP+/ mice suggests
that CBP is mainly functional in WAT. The effect of p300 depletion
on adipose depots in mice is not known: p300/ mice are fully
embryonic lethal, while p300+/ are partial embryonic lethal [63].
Bugge et al. have recently compared target gene regulation of
PPARc lacking the A/B domain with that of WT PPARc [64]. The
expression of only a small number of genes depended on the A/
B-domain. Interestingly, recruitment of p300 and CBP to these
genes was reduced, suggesting that the A/B domain of PPARc is
speciﬁcally involved in the recruitment or stabilization of CBP-
and p300-containing cofactor complexes to a subset of target
genes. In conclusion, there are several indications showing the
involvement of CBP and p300 in adipogenesis, but additional stud-
ies are required to establish how PPARc, p300 and CBP cooperate to
regulate adipogenesis in both WAT and BAT.
3.3. PPARc Coactivator-1 (PGC-1) family of coactivators
PGC-1a was originally identiﬁed in a two-hybrid experiment
using murine BAT cDNA and PPARc as bait [65]. The related PGC-
1b gene was subsequently identiﬁed by homology database
searches [66]. PGC-1a contains three LXXLL motifs and binds to
several NRs, in general in a ligand dependent manner (reviewed
by [67]). The interaction with PPARc however is ligand-indepen-
dent and mediated through a N-terminal domain and an LXXLL
motif [65,68]. It should be noted that PGC-1 coactivators also tar-
get other transcription factors involved in metabolism, like FOXO1,
SREBP, Foxa2 and Sox9 [69–72].
The physiological role of PGC-1 has been demonstrated in PGC-
1 knockout mouse strains. PGC-1a/mice have a reduced expres-
sion of mitochondrial genes in, amongst others, BAT, skeletal and
cardiac muscles and the brain, resulting in an impaired metabolic
response to stresses like cold exposure and starvation [73,74]. This
is in line with the role of PGC-1a as a cold induced coactivater reg-
ulating the expression of mitochondrial genes involved in adaptive
thermogenesis, like UCP1 [65]. In PGC-1b/ mice, mitochondrial
gene expression is also decreased in several tissues, including
BAT, liver, brain, skeletal and cardiac muscle [75,76], and these
mice are impaired in their adaptive thermogenesis after cold expo-
sure. This suggests that at least in mice PGC-1b plays a non-redun-
dant role in the control of mitochondrial oxidative energy
metabolism.
The role of gene regulation by PPARc in concert with PGC-1 has
not been studied extensively. PGC-1a, a PPARc target gene itself
[77], enhances PPARc-mediated UCP1 expression [65]. On the
other hand there are also indications that the expression of UCP1
can be regulated by other means, since also in BAT devoid of PPARc
UCP1 is expressed [78]. The classical PPARc target gene FABP4 is
not regulated by PGC-1a [65], while regulation of the glycerol ki-
nase (GyK) gene by PPARc does involve PGC-1a., showing that
there is gene target selectivity for PGC-1a [79]. To conclude,
PGC1-a and PGC1-b are important for mitochondrial oxidative
metabolism and hence for BAT function. They are highly differen-
tially expressed in BAT and WAT which reﬂects their BAT-speciﬁc
function. There are indications that PPARc is involved in PGC1-a
and PGC1-b mediated BAT-speciﬁc functions, but more extensive
studies are required to further elucidate the role of PPARc in BAT
function.3.4. Mediator subunits: TRAP220 and MED14
TRAP220 and MED14 are subunits of the Mediator complex.
This complex does not contain enzymatic activity, but is involved
in bridging the RNA polymerase II machinery with other coactiva-
tors [45]. TRAP220 was identiﬁed as a NR interacting protein in a
two-hybrid screen using PPARc as bait [80]. TRAP220 interacts
with PPARc in a ligand- and LXXLL-dependent way [80,81] and
its presence is required for PPARc2-stimulated adipogenesis of
mouse embryonic ﬁbroblasts (MEFs) [82]. Recently it was shown
that in undifferentiated TRAP220/MEFs, exogenous PPARc could
be recruited to and activate the FABP4 gene [83]. These ﬁndings
suggest that, depending on the cellular condition, TRAP220 is not
per se required for PPARc transcriptional activity, but there might
be redundancy with other Mediator subunits. In the same study it
was shown that both LXXLL motifs are dispensable for rescue of
adipogenesis in TRAP220/ MEFs, while on the other hand intact
LXXLL motifs were essential for PPARc function in a cell-free tran-
scription assay. This suggests that in a cellular context, TRAP220 is
required for PPARcmediated adipogenesis, but a direct interaction
with PPARc is not required.
The TRAP220 knockout mouse is not viable and dies around
embryonic day 11.5 due to defects in the development of placental
vasculature and due to cardiac failure [84,85]. To our knowledge it
is unknown if in heterozygous TRAP220+/mice adipogenesis is af-
fected. In general the role of TRAP220 in WAT and BAT develop-
ment has been studied scarcely. It has been reported that
TRAP220 is expressed in mouse BAT [86] and that it is involved
in PGC-1a mediated UCP1 expression [87]. Future studies with
for instance conditional knockout mice might shed light on the
speciﬁc role of TRAP220 in WAT and BAT.
Recently the Mediator subunit MED14 has been identiﬁed as a
novel PPARc coactivator involved in 3T3-L1 adipogenesis [88].
MED14 does not contain LXXLL motifs and interacts with the N-
terminus of PPARc in a ligand-independent manner. In addition,
MED14 mediates the binding of PPARc, MED6 and MED8 to the
proximal promoter of the FABP4 gene, but it is not involved in
PPARc binding to the FABP4 enhancer. Speciﬁc roles for MED14
in either BAT or WAT have not been described yet.
3.5. Other PPARc coregulators
In addition to the coregulators described above, also a number
of less well studied coregulators with a role in adipogenesis have
been identiﬁed recently.
Lipin-1 was originally identiﬁed as the mutant gene underlying
lipodystrophy in the fatty liver dystrophy (ﬂd) mouse [89]. The ﬂd
mouse lacks both normal WAT and BAT, reﬂecting an overall
requirement for Lipin-1 in adipocyte differentiation. Lipin-1 deﬁ-
cient cells and tissue fail to induce the expression of PPARc and
C/EBPa and hence their downstream target genes [90]. Next to
its ability to induce PPARc expression, Lipin-1 probably also acts
as a PPARc coactivator, as was demonstrated by the recruitment
of Lipin-1 to the PPRE of the PPARc target gene PEPCK [91]. mRNA
levels of Lipin-1 are equal in murine BAT and WAT [92], indeed
suggesting a general role for Lipin-1 in adipocyte differentiation.
Tip60, a member of the MYST family of acetyltransferases, was
identiﬁed by mass spectrometry as a novel PPARc coregulator [93].
It coactivates PPARc via and interacts with the PPARc AF-1 region
and its acetyltransferase capacity is required for this activation. In
addition, knock down of Tip60 abrogates 3T3-L1 adipocyte
differentiation.
Multiple Endocrine Neoplasia type 1 (MEN1) patients fre-
quently contain mutations in the MEN1 gene, encoding the menin
protein [94]. MEN1 patients often develop lipomas, while PPARc is
expressed in several MEN1-associated tumors. Menin is a subunit
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sine 4 of histone H3. Recently menin was identiﬁed as a coactivator
for PPARc [95]. Menin contains an LXXLL motif, but interacts with
the AF-2 of PPARc in a ligand- and LXXLL-independent way.
Remarkably, PPARc mediated gene activation by menin is ligand
dependent and requires both an intact LXXLL motif as well as an
intact PPARc helix 12. Both knock down studies in 3T3-L1 cells
and experiments in MEN1/ ﬁbroblasts show that menin is re-
quired for adipocyte differentiation [95].
CCPG (Constitutive Coactivator of PPARc) is another PPARc
coactivator identiﬁed by two-hybrid screening. CCPG interacts
with the hinge/D region of PPARc in a ligand-independent manner
and enhances the transactivation of PPARc [96]. Although the
CCPG protein contains four LXXLL motifs, none of them is required
for the interaction with PPARc. Overexpression or knock down
experiments in OP9 preadipocytes has shown that CCPG is in-
volved in the proces of adipogenesis [96].
The Thyroid Interacting Protein 3, Trip3, was originally identi-
ﬁed as an interaction partner of the Thyroid Hormone Receptor
[97]. Using a microarray based method to study the interaction be-
tween peptides containing LXXLL motifs derived from NR coactiva-
tors and the LBD of PPARc, we found that the LXXLL motif of TRIP3
interacts with PPARc in a ligand dependent manner [55]. Knock-
down of TRIP3 in 3T3-L1 cells led to impaired adipocyte differenti-
ation, showing its potential importance in adipogenesis.
PRIP (PPAR Interacting Protein) was identiﬁed in a two-hybrid
screen using PPARc as bait. PRIP interacts ligand-dependently
and via a LXXLL motif with PPARc and activates PPARc transcrip-
tion in a ligand dependent way [98]. PRIP knockout mice are
embryonic lethal, however PRIP/ MEFs exhibit impaired
PPARc-mediated adipogenesis, suggesting that coactivation of
PPARc by PRIP is required for adipogenesis.
Castillo et al. [99] performed a two-hybrid screen with the AF-1
domain of PPARc. One of the interacting proteins they identiﬁed
was PGC-2/SCAND1. PGC-2 is able to increase the transcriptional
activity of PPARc and overexpression of PGC-2 in 3T3-L1 cells leads
to increased adipocyte differentiation. No mouse model is available
for PGC-2 and no speciﬁc role for PGC-2 has been described in WAT
or BAT.
3.6. PRDM16
By comparing the mRNA expression levels of transcription-re-
lated genes in mouse WAT and BAT, Seal and co-workers identiﬁed
PRDM16 as a BAT-speciﬁc transcription factor [100]. PRDM16 is a
zinc ﬁnger protein which was ﬁrst identiﬁed at a chromosomal
breakpoint in myeloid leukemia [101]. Overexpression of PRDM16
in cultured white preadipocytes results in activation of the brown
adipose differentiation program, with upregulation of mitochon-
drial genes. This is accompanied by an increase of mitochondrial
biogenesis and uncoupled respiration, hallmarks of BAT. In con-
trast, knock down of PRDM16 in brown adipocytes ablates the
brown adipocyte characteristics [100]. These data highly suggests
that PRDM16 serves as a molecular switch which determines adi-
pose tissue to become white or brown. In a follow-up study, the
role of PRDM16 was further speciﬁed as being a cell fate switch be-
tween skeletal myoblasts and brown adipocytes [11], two cell
types which both are derived from myf5 positive precursor cells.
Indeed, PRDM16 is able to induce brown adipogenesis in myogenic
cells [11]. PRDM16 deﬁcient mice die at birth, but late-stage em-
bryos (E17) show severely affected BAT, with decreased expression
of BAT selective and thermogenic genes, and simultaneously en-
hanced expression of skeletal myogenic genes [11]. PRDM16
immunopuriﬁcation followed by mass spectrometry analysis iden-
tiﬁed PPARc as a component of the PRDM16 complex. PRDM16 is
able to bind to PPARc in a ligand-independent manner and en-hances the transcriptional activity of PPARc. PRDM16 is unable
to promote adipogenesis in PPARc/ ﬁbroblasts and the conver-
sion of primary myoblasts by PRDM16 is largely dependent on
the presence of the TZD rosiglitazone. This indicates that PPARc
activation is required for the adipogenic function of PRDM16.
Hence, PRDM16 not only works as a DNA binding transcription fac-
tor, but also as a PPARc coactivator.
3.7. NCoR, SMRT and other corepressor proteins
NCoR and SMRT were the ﬁrst identiﬁed NR corepressors
[48,49]. Both proteins form complexes which contain histone
deacetylation activity (reviewed in [102]). NCoR and SMRT are
highly homologous, and contain three and two CoRNR boxes,
respectively [50,103–106]. Both NCoR/ and SMRT/ mice dis-
play an embryonic lethal phenotype. The NCoR/mice display de-
fects in CNS, erythrocyte and thymocyte development, while the
SMRT/ mice have aberrant forebrain structures and die due to
a lethal heart defect [107,108]. Nofsinger et al. generated a
knock-in mutation in the receptor interacting domain of SMRT,
which disrupts its interaction with NRs. These mice exhibit a num-
ber of metabolic defects, including improved insulin sensitivity and
increased adiposity, which were attributed to enhanced PPARc
activity [109]. SMRT+/ mice develop increased adiposity on a
high-fat diet and MEFs derived from these mice show increased
adipogenesis. Also insulin sensitivity was enhanced in SMRT+/
adipocytes [110]. In the 3T3-L1 system PPARc2 is able to recruit
NCoR and SMRT and both coregulators repress PPARc2-mediated
gene transcription [106]. Additional studies showed the recruit-
ment of NCoR and SMRT to PPARc target genes in a promoter spe-
ciﬁc way. PPARc recruits NCoR and SMRT to the glycerol kinase
promoter and both corepressors are released upon ligand stimula-
tion. However, in case of the aP2 promoter there is no recruitment
of either corepressors [79].
The differential role of NCoR and SMRT in WAT and BAT physi-
ology is not clear. To our knowledge, no studies have been per-
formed to analyse the speciﬁc role of NCoR and SMRT in both
WAT and BAT.
SIRT1, a NAD+-dependent deacetylase, interacts with PPARc and
represses PPARc mediated transcription by docking with NCOR
and SMRT [111]. SIRT1 binds to the aP2 promoter upon fasting
and SIRT+/ mice displayed a decreased release of free fatty acids
upon fasting. Furthermore, overexpression of SIRT1 triggers lipo-
genesis and adipogenesis [111]. These data imply that SIRT1 is in-
volved in the regulation of adipogenesis by PPARc upon caloric
restriction. It was hypothesized that SIRT1 might be involved in
regulating the brown adipocyte differentiation by preventing myo-
blast differentiation as well as promoting mitochondrial biogenesis
[112]. Comparison of gene expression proﬁles of SIRT1 over-
expressing myoblasts and differentiating brown pre-adipocytes
showed a large overlap of regulated genes, which strengthens this
hypothesis.
The Receptor Interacting Protein 140 (RIP140) is a NR coregula-
tor which is involved in both activation and repression of NR-med-
iated transcription (reviewed in [113]). It contains nine LXXLL
motifs and four repression domains and mainly acts as a scaffold
that links NRs to chromatin remodelling enzymes. RIP140 is able
to interact with PPARc in a ligand dependent way [114] and we
have shown that some of the LXXLL motifs of RIP140 interact with
PPARc in a ligand dependent manner [55]. Physiologically, RIP140
is involved in regulating the energy expenditure in adipose tissue.
RIP140/ mice are leaner than their control littermates, which is
not due to a defect in adipogenesis, but which is caused by dere-
pression of energy expenditure genes (e.g. UCP1) in WAT
[115,116]. This latter observation suggests that RIP140 suppresses
brown adipose speciﬁc gene transcription in WAT.
Fig. 2. Differential expression of NR coregulators in mouse WAT and BAT. Microarray data from Seale et a. [100] was retrieved from the Gene Expression Omnibus site of the
National Center for Biotechnology Information (NCBI) (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE8044). This set contains gene expression proﬁles of three
samples of mouse epididymal WAT (white s.1–s.3) and three samples of interscapular BAT (brown s.1-s.3), all analysed with the Affymetrix Mouse Genome 430 2.0 Array
platform. We coupled the list of all NR coregulators known in the Nuclear Receptor Signalling Atlas (NURSA) database to the gene expression dataset and compared
expression of NR coregulators in WAT and BAT using the Student’s t-test. We depicted all the NR coregulators which are differentially expressed (P < 0.001). For each gene the
expression is normalized to the average expression of that particular gene in the six samples. The names of the coregulators according to the NURSA website and the Human
Genome Organization (HUGO) are depicted, as well as the activity (A = activating, R = repressing, A/R = both activating and repressing), the motifs involved in the interaction
and the interacting NRs.
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been reported. TRB3 encodes a kinase involved in promoting lipid
metabolism during fasting. Qi et al. generated transgene mice con-
taining TRB3 under the control of the aP2 promoter [117]. These
mice display a lean phenotype, with reduced weight of WAT,
whereas BAT mass is not decreased. Although this effect was
attributed to the inactivation of acetyl-coenzyme A carboxylase,
it also has been reported that TRB3 interacts with PPARc, whereby
it inhibits PPARc mediated transcription, leading to suppression of
adipocyte differentiaton [118]. The observation that TRB3 overex-
pression had no effects on BAT, suggests that its action is speciﬁc
for WAT.
The ﬁnal corepressor which will be discussed here is TAZ. The
function of this protein is largely unknown, but it can act as a tran-
scriptional coactivator or corepressor [119]. Hong and co-workers
demonstrated that TAZ is able to modulate the differentiation of
MSCs into osteoblasts or adipocytes: TAZ represses adipogenesis
by inhibiting PPARc-dependent transcription, while at the same
time stimulating osteoblast differentiation by stimulating the tran-
scription factor Runx2. Furthermore, knockdown of TAZ in 3T3-L1
cells resulted in increased adipocyte differentiation [120], under-
scoring the repressive function of TAZ in adipogenesis. A direct
interaction between TAZ and the AF-1 domain of PPARc has been
shown which requires the TAZ WW domain. The study of Hong
et al. [120] shows that TAZ can determine the cellular fate of MSCs;
whether TAZ is also involved in BAT development is currently
unknown.
4. Identiﬁcation of new PPARc coregulators involved in WAT
and BAT development
In this paper a number of PPARc coregulators involved in adipo-
genesis have passed in review. Also a selected set of these coregu-
lators is involved in the development of WAT or BAT speciﬁcally.
Since over 250 NR coregulators (www.nursa.org) have been identi-
ﬁed to date, it may be expected that there are more PPARc coreg-
ulators involved in white and/or brown adipogenesis. We used the
microarray datasets of Seale et al. [100] in combination with the
list of NR coregulators from the Nuclear Receptor Signalling Atlas
(www.nursa.org), to identify NR coregulators differentially ex-
pressed in WAT versus BAT (Fig. 2). This microarray dataset con-
tains gene expression proﬁles of three murine WAT samples and
three BAT samples of three male C57Bl/6 mice at 10–12 weeks of
age. In Fig. 2 we listed 77 coregulators which show differential
expression. Strikingly, 68 coregulators displayed higher expression
in WAT compared to BAT, while only 9 genes displayed a higher
expression in BAT than inWAT. Interestingly, the mRNA expression
levels of the corepressors NCoR and SMRT are higher in WAT than
in BAT. It may therefore be hypothesized that both proteins might
be involved in determining the distinctive properties of WAT and
BAT, for instance by repressing brown-speciﬁc PPARc target genes
in WAT, as already has been shown for the repression of UCP1 by
RIP140 in WAT [115,116]. To investigate this possibility it is neces-
sary to study the physiological role of NCoR and SMRT in WAT and
BAT in more detail. In addition, it would be interesting to over-ex-
press NCoR and SMRT in brown adipocytes to see if a transition
from brown to white phenotype can be effectuated. CBP mRNA
expression is higher in WAT than in BAT, suggesting a WAT-spe-
ciﬁc role for CBP. This is in line with the CBP+/ mouse model,
where WAT is affected and not BAT [62]. Strikingly, also the p300
mRNA expression is higher in WAT than in BAT, also suggesting
that p300 might be involved in WAT and BAT speciﬁcity. The high-
er expression of SRC-1 in WAT is surprising, since SRC-1 together
with PGC1a is involved in regulating adaptive thermogenesis
[53]. The microarray data also shows that PGC-2 expression ishigher in WAT compared to BAT, suggesting that also this coactiva-
tor may be involved in WAT-speciﬁc PPARc transcription. Both
PGC-1a and PGC-1b displayed a higher expression in BAT than in
WAT, which is in accordance with the role of the PGC-1 proteins
in BAT mediated adaptive thermogenesis.
A number of coregulators discussed in this review, including
Tip60, menin, CCPG and TRIP3, do not show differential expression,
indicating that these coregulators may have general, and not BAT-
or WAT-speciﬁc functions in adipocyte differentiation. More re-
search with (conditional) mouse models in combination with
experiments in white and brown adipocyte cells is required to fur-
ther address the speciﬁc function of these coregulators in BAT and
WAT.
The list presented in Fig. 2 also includes a large number of
coregulators which have not been associated with PPARc thus
far. It would be interesting to further investigate these coregulators
for (i) a possible interaction with PPARc, (ii) their role in adipogen-
esis, and (iii) their speciﬁc roles in WAT and BAT.
5. Conclusions and perspectives
The interest in the mechanisms underlying WAT and BAT devel-
opment has increased the last few years, not in the least because
conversion of WAT into BAT may be therapeutically beneﬁcial in
the ﬁght against obesity and its associated disorders. The discovery
that BAT is present in human adults together with the discovery of
PRDM16 as a BAT determinant has raised the interest in this sub-
ject considerably. Although PRDM16 is an important player in
the development of BAT, it is likely that there are more proteins in-
volved in determining adipocyte fate. In this review we have fo-
cused on PPARc coregulators which are involved in adipogenesis
in general andWAT and BAT development in particular. So far, only
few PPARc coregulators have been reported to have speciﬁc roles
in WAT and BAT speciﬁcation (SRC-1, SRC-2, RIP140 and PGC-
1a). On the other hand, a number of coregulators we have dis-
cussed show differential expression in WAT compared to BAT,
including NCOR, SMRT and p300, suggesting that these coregula-
tors might also be involved in determining BAT/WAT identity. In
addition, more NR coregulators show differential expression,
although it is unknown if these coregulators mediate PPARc signal-
ling. Future research could give insight in the role of these coregu-
lators in WAT and BAT and could provide us with new targets for
therapeutic intervention in the treatment of obesity.
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